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AbsTrACT
background Heterozygous germline loss-of-function 
mutations in the aryl hydrocarbon receptor-interacting 
protein gene (AIP) predispose to childhood-onset 
pituitary tumours. the pathogenicity of missense 
variants may pose difficulties for genetic counselling 
and family follow-up.
Objective to develop an in vivo system to test the 
pathogenicity of human AIP mutations using the fruit 
fly Drosophila melanogaster.
Methods We generated a null mutant of the 
Drosophila AIP orthologue, CG1847, a gene located 
on the Xchromosome, which displayed lethality at 
larval stage in hemizygous knockout male mutants 
(CG1847exon1_3). We tested human missense variants 
of ’unknown significance’, with ’pathogenic’ variants 
as positive control.
results We found that human AIP can 
functionally substitute for CG1847, as heterologous 
overexpression of human AIP rescued male 
CG1847exon1_3 lethality, while a truncated version of 
AIP did not restore viability. Flies harbouring patient-
specific missense AIP variants (p.c238Y, p.i13n, 
p.W73r and p.g272D) failed to rescue CG1847exon1_3 
mutants, while seven variants (p.r16H, p.Q164r, 
p.e293V, p.a299V, p.r304Q, p.r314W and p.r325Q) 
showed rescue, supporting a non-pathogenic role for 
these latter variants corresponding to prevalence and 
clinical data.
Conclusion Our in vivo model represents a valuable 
tool to characterise putative disease-causing human 
AIP variants and assist the genetic counselling and 
management of families carrying AIP variants.
InTrODuCTIOn
Pituitary adenomas arise from hormone-se-
creting cells of the anterior pituitary gland. The 
presenting symptoms are due to either excess 
or deficiency of pituitary hormones or local 
space-occupying effects. Loss-of-function muta-
tions in the aryl hydrocarbon receptor-interacting 
protein gene (AIP) predispose to an autosomal 
dominant disorder with incomplete penetrance 
(20%–23%) associated usually with growth 
hormone-secreting pituitary adenomas leading to 
acromegaly or gigantism.1–3 To date, more than 
100 different AIP variants have been identified, 
with the majority (75%) resulting in a missing or 
truncated AIP protein.2 3 A change in amino acid 
sequence due to missense variants could affect 
protein folding and stability4 and may alter 
the availability of protein–protein interaction 
sites. The C-terminus of AIP includes conserved 
tetratricopeptide repeat (TPR) domains, and 
alterations in key amino acids are known to 
disrupt secondary structure, leading to unstable 
proteins.5–7 While pathogenicity is beyond doubt 
for the truncating mutations, establishment of 
pathogenicity for missense variants can be chal-
lenging, posing therefore a key question for clin-
ical genetic counselling and decision making.8
The strategies employed to establish patho-
genicity for heterozygous tumour suppressor 
genes, such as AIP, include: allele frequency in 
the general population, loss of the wild-type 
(wt) allele in the tumour (loss of heterozygosity 
(LOH)), in silico prediction pipelines,9 in vitro 
functional studies and evaluation of variant segre-
gation with the phenotype in large pedigrees.10 
LOH analysis of tumourous tissue has also been 
exploited to determine the pathogenic role of 
AIP variants,11 12 and AIP immunostaining is 
significantly reduced in the majority but not in 
all patients carrying AIP mutations.13–15 In vitro 
functional studies have also been employed to 
evaluate the protein stability of AIP variants,4 
their effect on cell proliferation13 and their inter-
action with PDE4A513 16 and RET,17 but these 
assessments are necessarily indirect.
However, the in vivo consequences of AIP 
missense variants have never been investigated. 
We aimed to develop an in vivo strategy to help 
determine the pathogenicity of missense AIP 
variants.
MATerIAls AnD MeThODs
Fly stocks and genetics
The Drosophila melanogaster strains used in this 
study: wiso (gift from Nic Tapon, London, UK), 
yw;Bl/CyO (Lindsley and Zimm),18 w* P{EP}
CG1847G1839 (Bloomington Drosophila Stock 
Center: Stock ID: 32600),19 yw;; Ki, pp, Δ2–3, 
P{CaryP}attP40 embryos (BestGene Inc, Cali-
fornia, USA) and yw; Act-Gal4/CyO.
Drosophila husbandry
Fly crosses were maintained at 25°C. For 
counting, the rescued males crosses were flipped 
every 9–10 days to prevent the mix of individual 
flies from different generations.
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Generation of mutant CG1847 flies: imprecise excision 
screen
The CG1847 gene was mutated by P-element transposase-mediated 
deletion of genomic DNA. For this, a fly line was obtained, in which 
a P-element is inserted within the 5′UTR of CG1847: w*P{EP}
CG1847G1839 (Bloomington Drosophila Stock Center).20 Females 
homozygous for the CG1847 mutation are not viable, while hetero-
zygous mutant females develop normally. The resulting stocks were 
screened by PCR, and the putative mutants were identified via 
Sanger sequencing. Sequence chromatograms were visualised and 
analysed using the BioEdit Sequence Alignment Editor software 
(http://www. mbio. ncsu. edu/ bioedit/ bioedit. html) (Ibis Biosciences, 
Carlsbad, California, USA).
rescue of CG1847 function
A genomic rescue construct containing the regulatory and coding 
regions of CG1847 (2763 bp) was generated, cloned into the pW@
RpA vector (kindly provided by Professor Nick Brown's laboratory, 
Cambridge, UK, details available on request).
To obtain the genomic rescue construct for hAIPwt, the AIP 
cDNA insert (1001 bp) was amplified from a pcDNA3-Myc-AIPwt 
vector.13 To obtain the genomic rescue construct of truncated AIP, 
the last 86 bp encoding for the seventh alpha helix were deleted. 
Transgenic lines for 11 different hAIP mutations (p.I13N, p.R16H, 
p.W73R, p.Q164R, p.C238Y, p.G272D, p.E293V p.A299V, 
p.R304Q, p.R314W and p.R325Q) were also generated. Muta-
genic primers were designed using the Stratagene’s QuickChange 
Primer Design program at www. stratagene. com/ qcprimerdesign. 
The QuickChange XL Site-Directed Mutagenesis kit (Agilent Tech-
nologies) was used, and mutagenesis was done according to stan-
dard recommended procedure.
All transgenic lines were generated by injecting the rescue 
constructs into Drosophila y1w67c23; P{CaryP}attP40 embryos, 
which enabled the generation of transgenic stocks with constructs 
on chromosome 2. These transgenic fruit flies stocks were balanced 
over the balancer chromosome CyO. For males resulting from the 
rescue crosses, the hAIP transgene (online supplementary figure 
4B,C: middle panels) was detected using primers against human AIP 
cDNA. In addition, the presence of Y chromosome (bottom panels) 
was detected using a set of primers for the Ppr-Y gene.
statistical analysis
Experimental data sets were analysed in JMP (SAS institute). 
Statistical comparisons were analysed with one-way anal-
ysis of variance followed by a Tukey-Kramer test. Data are 
presented as mean ±SEM. A value of P<0.05 was considered 
to be statistically significant.
Western blotting analyses
The different UAS (Upstream Activation Sequence) insertions 
for the human AIP were confirmed to drive protein expression 
in combination with the actin-GAL4 using specific commer-
cially available antibody. The Western blots were incubated 
overnight, at 4°C, with primary antibody anti-AIP/ARA9 Mouse 
Monoclonal21 (Novus Biologicals) at a dilution of 1:1000. Anti-
Beta Tubulin, Mouse monoclonal (E7 Developmental Studies 
Hybridoma Bank)22 was used as a loading control at a dilution 
of 1:15 000. Secondary antibody IRDye 680 LT Goat anti-Mouse 
IgM (LI-COR Biotechnology) was used at a concentration of 
1:1000. Odyssey Infrared Imaging System (LI-COR) was used 
for image acquisition. Results are representative of four indepen-
dent western blot analyses from two independent experimental 
replicates.
resulTs
Characterisation of the Drosophila orthologue of human AIP
The D. melanogaster gene CG1847 (NM_132530.4)23 is the 
fruit fly’s single orthologue of human AIP. This three-exon gene 
is located on chromosome X at position 10F2, base pair (bp) 
11 869 170 to 11 871 168 (Drosophila genome release August 
2014). As it is located on the X chromosome, male flies will have 
only one copy of this gene.
CG1847 is a previously uncharacterised Drosophila gene, and 
no phenotypic fruit fly data are available in public databases. 
Protein alignment of CG1847 (FBtr0073567) and human AIP 
(hAIP, ENST00000279146) was performed by Clustal Omega24 
and revealed a shared overall identity of 38% (Figure 1A). The 
three-dimensional theoretical model of CG1847 (Figure 1B) 
revealed a protein structure that closely resembles the published 
AIP protein structure , with a typical N-terminal peptidyl-prolyl 
cis-trans isomerases (PPIase)-like domain25 and the C-terminal 
TPR domains.26
Figure 1 comparison of Drosophila cg1847 and human aiP proteins. (a) the human and Drosophila proteins are similar; they share 120 identical 
amino acids, 80 strongly conserved and 34 weakly conserved amino acids. Stars indicate identity, and colons and dots indicate high and low similarity 
amino-acids, respectively. (B) a three-dimensional predicted model of cg1847 indicates that the Drosophila protein has a similar structure to its human 
orthologue, with an n-terminal PPiase domain, three pairs of conserved antiparallel alpha-helices forming the tetratricopeptide repeat domains (tPrs) and 
the final extended α-helix, α−7. aiP, aryl hydrocarbon receptor-interacting protein gene.
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CG1847 is an essential gene and its loss results in early 
lethality
We used imprecise P-element excision27 to generate a loss-of-
function mutations in CG1847 (Figure 2A). One of the resulting 
lines harboured an excision of 2511 bp covering all three exons 
(CG1847exon1_3, Figure 2A-ii). The deletion did not extend into the 
neighbouring genes CG2025 and CG11802, positioned 279 bp and 
129 bp downstream of the CG1847 5′ and 3′ UTR regions, respec-
tively. CG1847 is located on the X chromosome, and no viable 
hemizygous males were observed carrying this mutation. Because 
heterozygous females were normal, viable and fertile, this suggests 
that complete loss of CG1847 leads to lethality, similarly to mouse 
knockout models.28 29
To demonstrate that lethality of CG1847exon1_3 is solely due to the 
deletion of CG1847 coding sequence and not caused by additional 
mutations generated by the imprecise excision, transgenic flies 
carrying a genomic rescue construct on chromosome 2, containing 
the wt regulatory and coding regions of CG1847 (Figure 2A-iii), 
were generated and injected into Drosophila embryos (BestGene). 
Transgenic male flies were crossed with heterozygous CG1847exon1_3 
mutant females (Figure 2B) to study the ability of the wt CG1847 
rescue construct to reverse the lethality of CG1847exon1_3 males. 
Hemizygous mutant CG1847exon1_3 males expressing the wt 
CG1847 construct on chromosome 2 were viable (Figure 2B, 
panel i), suggesting that lethality of CG1847exon1_3 flies is indeed 
due to loss of CG1847. The degree of rescue was determined by 
analysing the proportion of each viable male genotype in the second 
generation (Figure 2C). All offspring without endogenous CG1847 
or without the rescue construct (Figure 2B, panel iii) died at the 
larval stage. However, a small number of males without the rescue 
construct, but phenotypically similar to males in Figure 2B, panel iii, 
were viable due to a meiotic non-disjunction event in the previous 
generation, a low-frequency phenomenon common in Drosophila 
genetics (online supplementary material 1, figures 1–3). 30–33
human AIP is able to functionally compensate for CG1847 
loss
Since CG1847-deficient males die at an early larval stage, they 
could serve as a useful model to test the functional conservation 
between human and Drosophila AIP. We used the UAS-GAL4 
system to express a human AIP (UAS-hAIP) transgene under 
the control of a ubiquitously active promoter (actin-Gal4) and 
Figure 2 the lethality of CG1847 mutants can be rescued by expression of wild-type (wt) CG1847 under the control of its own promoter. (a) Schematic 
diagram of the wt CG1847 (i), CG1847exon1_3 (ii), CG1847 rescue construct and (iii) transgenic generated human AIP rescue construct (iv). the diagram 
represent the mrna, with red boxes representing coding region and white boxes representing 5′ and 3′ untranslated regions. (ii) the CG1847 mutant was 
generated by imprecise P-element excision of P-cg1847g1839 (eP in the figure). (iii) Schematic representation of transgenic animals with genomic rescue 
construct containing the regulatory and coding regions of CG1847 inserted on the second chromosome. (iv) Schematic representation of transgenic animals 
with the AIP cDna rescue construct inserted on the second chromosome. (B) transgenic males carrying the CG1847 genomic rescue construct and balanced 
over cyO were crossed to the CG1847exon1_3 heterozygous females and examined for their ability to rescue male lethality. Segregation of alleles and the 
possible combinations are shown in the lateral panels. Panel (i): male carrying the mutant CG1847 allele inherited from their mothers rescued by the wt 
CG1847 allele on the second chromosome. Panel (iii): males are not viable as they carry the CG1847 mutant allele and lack the genomic rescue construct 
from the paternal chromosome 2. Panels (ii) and (iv) depict male progeny lacking the CG1847 mutation. (c) Statistical analysis of rescue experiments 
with the CG1847 genomic rescue construct (n=4). the associated letters (panels i–iv) correspond to the phenotypes depicted in Figure 2B. X-axis labels 
CG1847-1M and CG1847-3M represent two different transgenic stocks carrying the rescue construct. error bars represent Se of the mean. asterisks indicate 
statistical significance as determined by Student’s t-test (**P<0.01). aiP, aryl hydrocarbon receptor-interacting protein gene; bp, base pairs.
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assessed its ability to rescue the lethality of CG1847 mutant 
males. Ubiquitous expression of UAS-hAIP-wt was able to func-
tionally replace CG1847 and rescue the lethality of Drosophila 
CG1847exon1_3 mutants (Figure 3A), confirming that AIP is func-
tionally conserved between flies and humans. Moreover, the 
proportion of viable F1 males carrying the rescue hAIP construct 
was close to the expected proportion (33% observed vs 25% 
expected in case of full rescue, corresponding to 1 of 4 viable 
genotypes). Flies expressing the UAS-hAIP-wt construct could 
therefore be used as a positive control for testing hAIP variants 
with unknown significance identified in patients with pitu-
itary adenomas. We also generated transgenic flies with a hAIP 
construct containing a truncation mutation of the last α-helix 
of the AIP protein—known to be crucial for AIP function26 34—
and used this as a positive (pathogenic) control representing a 
non-functional AIP protein (Figure 3B). This truncated hAIP was 
unable to rescue the CG1847exon1_3 mutant as no viable males 
were found expressing the truncated hAIP variant (Figure 3C).
human AIP missense variants differ in their ability to rescue 
CG1847 insufficiency
Having demonstrated that wt hAIP expression in CG1847 
knockout flies is able to rescue male lethality, while a trun-
cated version is not, we next tested the rescue ability of 11 
hAIP missense variants (p.I13N, p.R16H, p.W73R, p.Q164R, 
p.C238Y, p.G272D, p.E293V, p.A299V, p.R304Q, p.R314W 
and p.R325Q), found as germline variants in patients with pitu-
itary adenomas (Figure 3B).
Out of all these tested variants, we selected one known to 
be a relatively common polymorphism (p.R16H) as a nega-
tive control, and two variants, a truncation mutation and the 
p.C238Y missense pathogenic mutation, as positive controls. 
There are considerable amount of data showing that p.R16H 
is a benign variant; it does not segregate with the disease35 
and various in silico predictions and functional studies (online 
supplementary material 2) suggest that it is a benign polymor-
phism.36 Truncating variants are known to be pathogenic, while 
the p.C238Y missense variant is also known to be pathogenic, 
based on segregation, in silico testing, in vitro functional studies 
(cell proliferation13 and the PDE4A5 binding assays16) and half-
life data4 (online supplementary material 2).
Given that all transgenes were site-specifically integrated into 
the genome, they are predicted to be expressed at similar levels. 
Clinical and genetic data available for these missense variants are 
presented in online supplementary material 2.
For each missense variant, we compared the proportion of 
rescued males with the corresponding proportion obtained with 
the wt and truncated hAIP controls (Figure 3C). hAIP variants 
separated into two groups: the p.R16H, p.Q164R, p.E293V, 
p.A299V, p.R304Q, p.R314W and p.R325Q variants rescued 
the lethal CG1847exon1_3 phenotype at a similar rate as wt hAIP 
(Figure 3C). In contrast, four missense variants (p.C238Y, 
p.I13N, p.W73R and p.G272D) were unable to rescue the male 
lethality of CG1847 mutants (P=0.0001) similar to the trun-
cated AIP variant. The data obtained using our in vivo model 
supports and strengthens the clinical and bioinformatics data 
Figure 3 Human AIP functionally complements the Drosophila orthologue. (a) transgenic males with hAIP rescue construct were crossed to heterozygous 
CG1847 deficient females. the ubiquitous actin-Gal4 driver was used to drive the expression of the UAS-hAIP constructs during fly development. Panel 
(i) images of F1 viable rescued males. Males expressing wt hAIP in the CG1847 mutant background (mutant CG1847 allele inherited from their maternal 
X chromosome and expression of the hAIP transgene on chromosome 2); panels (iii) and (v): males inheriting the mutant CG1847 allele and lacking 
haiP expression are not viable. these two genotypes also serve as internal negative controls. Panels (ii) and (iv): males lacking the CG1847 mutation are 
viable. (B) Schematic diagram of UAS-hAIP constructs. top, wt UaS-hAIP. Second line: artificially generated truncated haiP lacking the seventh alpha helix. 
transgenic lines for 11 different hAIP missense mutations (p.r16H, p.c238Y, p.a299V, p.r304Q, p.i13n, p.W73r, p.Q164r, p.g272D, p.e293V, p.r314W and 
p.r325Q) were also generated. the approximate position of amino acid changes introduced are indicated with an asterisk. Protein domains are indicated by 
the colour code shown below the deletion construct assembly (the colours of the domains match what is shown in the 3D model, Figure 1). (c) Quantitative 
analysis of in vivo rescue experiments using hAIP missense variants (n=6). Successful rescue of lethality was scored as the presence of males with the 
genotype CG1847exon1_3/Y; actin-Gal4/UAS-hAIP, which lacks endogenous CG1847. error bars represent Se of the mean. Significant differences are indicated 
by asterisks (****P<0.0001). aiP, aryl hydrocarbon receptor-interacting protein gene; tPr, tetratricopeptide repeat; wt, wild type.
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indicating that p.C238Y, p.I13N, p.W73R and p.G272D AIP 
variants are pathogenic. However, our findings suggest that the 
p.R16H, p.Q164R, p.E293V, p.A299V, p.R304Q, p.R314W and 
p.R325Q variants are functionally normal sequence alterations 
in our experimental setting.
hAIP rescue constructs have equivalent expression levels
As ubiquitous expression of wt, p.R16H, p.Q164R, p.E293V, 
p.A299V, p.R304Q, p.R314W and p.R325Q hAIP resulted in 
rescue of CG1847exon1_3 mutant males, total protein was extracted 
from fly heads to perform western blot analysis. Analysis of hAIP 
protein in fly lysates revealed a 37 kDa band, equivalent to the 
band detected in human HEK293T cells used as positive control 
(figure 4). The various hAIP constructs show similar protein 
expression levels (figure 4). Normal flies (wiso) were used as a 
negative control to confirm that the AIP antibody we used does 
not detect the endogenous CG1847 protein. In addition, trans-
genic males carrying the UAS-hAIP constructs only, without a 
Gal4 driver, did not display a hAIP band, excluding any detect-
able ‘leakiness’ of the transgenic UAS constructs (online supple-
mentary figure 5).
While the p.R16H, p.Q164R, p.E293V, p.A299V, p.R304Q, 
p.R314W and p.R325Q hAIP missense constructs were able 
to rescue male lethality and displayed robust AIP expression 
(figure 4) similar to the level of wt hAIP, lysates from non-dis-
junction males (resulting from crosses with females carrying the 
p.I13N, p.W73R or p.G272D transgenes, figure 4, marked as *) 
did not contain human AIP protein. This confirmed that these 
males are indeed resulted from a non-disjunction event and are 
viable due to a normal copy of CG1847 (online supplementary 
figure 4).
DIsCussIOn
Patients with loss-of-function AIP mutations suffer from pitu-
itary adenomas. For missense variants, the assessment of the 
functional and physiological consequences is hampered by the 
lack of robust in vitro and in vivo assays. In the era of increasing 
sequence data on human subjects, one of the most challenging 
issues is distinguishing pathogenic from non-pathogenic vari-
ants. In this study, combining a knockout for CG1847 with the 
Gal4/UAS binary expression system, we developed and opti-
mised an in vivo system to ‘bioassay’ the pathogenicity of AIP 
variants found in patients with pituitary tumours.37
We have found that deletion of the CG1847 results in lethality, 
similarly to AIP knockout mouse models,28 29 and re-introduction 
of CG1847 rescued this phenotype, demonstrating the spec-
ificity of our KO model. We then exploited the experimental 
power of Drosophila genetics to evaluate the degree of func-
tional conservation between human AIP and its fly orthologue 
by testing whether CG1847exon1_3 mutant flies could be rescued 
by human AIP.
A study of 287 human disease genes found a total of 178 
(62%) genes having likely homologues in Drosophila.38 Align-
ment of the human and fruit fly AIP proteins shows almost 40% 
identity, similar to the average level of protein identity between 
Drosophila and mammals.39
As the human gene was able to functionally compensate for 
the deletion of the Drosophila orthologue, our data support the 
evolutionary conservation of AIP gene function.
Furthermore, we have examined the effects of AIP variants 
in our Drosophila model in order to determine their pathoge-
nicity. If a specific AIP variant rescues the lethality phenotype 
of CG1847exon1_3 mutant flies, this strongly suggests that the 
variant does not cause a major disruption of AIP function, at 
least with regard to Drosophila development. Conversely, failure 
to rescue the lethality phenotype indicates the variant is likely 
to be non-functional and could account for the human disease.
We investigated 11 AIP missense mutations identified in 
patients with pituitary adenoma. Summary of these mutations 
are listed in table 1 and further detailed in online supplementary 
material, part 1. Our negative and positive controls confirmed 
the validity of the assay; p.R16H rescued the lethality to a level 
similar to wt AIP, while the truncated and p.C238Y variants 
failed to do so.
The lethality of CG1847exon1_3 mutants was rescued by 7 of the 
11 tested hAIP missense variants (p.R16H, p.Q164R, p.E293V, 
p.A299V, p.304Q, p.R314W and p.R325Q), while four variants 
(p.C238Y, p.I13N, p.W73R and p.G272D) failed to do so. These 
data suggest that the latter four variants have a significant func-
tional impairment or are unstable4 and therefore could represent 
pathogenic variants (see further discussion on these variants in 
online supplementary material 2). A similar strategy has previ-
ously been used to understand the conservation, functional 
role or importance of specific protein domains in human and 
Drosophila orthologues40–43 and could be employed to support 
clinical decision making.
Determining whether a variant is a disease-causing one is a 
significant challenge in the management of patients carrying a 
missense AIP variant,8 or indeed in any other partially penetrant 
disease.36 Evaluation of variant segregation with the phenotype 
Figure 4 the different aiP constructs, wild-type human AIP (haiP-wt) and various missense variants, show equivalent expression levels when ubiquitously 
expressed using the actin-Gal4 driver. cg1487 protein expression was not detected in wild-type flies (wiso), suggesting the anti-aiP antibody is specific for 
the human protein and does not recognise endogenous cg1487. β-tubulin was used as loading. Surviving males i13n*, W73r* and g272D* are viable as 
they have endogenous cg1487 but no haiP due to non-disjunction (further details of the non-disjunction phenomenon is presented in online supplementary 
material 1). aiP, aryl hydrocarbon receptor-interacting protein gene.
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in large pedigrees is the initial approach for investigating rare 
mutations.10 However, in case of AIP variants, this method is less 
practical due to the incomplete penetrance of the disease and the 
rarity of large families. Currently, there is no single method that 
can invariably predict the correct American College of Medical 
Genetics and Genomics (ACMG) category (‘pathogenic’, ‘likely 
pathogenic’, ‘uncertain significance’, ‘likely benign’ and ‘benign’) 
for missense variants. Although in silico prediction pipelines are 
often used, their results are not reliable, as shown recently, for 
endocrine genes including AIP.36 In addition to clinical data, 
such as segregation and variant frequency in the general popu-
lation, various in vitro and in vivo methods could be used to 
help in the decision making. Inevitably, all methods have pitfalls. 
In vitro studies may not accurately recreate the environment 
present in a living organism. In the case of missense mutations, 
the change in amino acid sequence could disrupt their tertiary 
structure, with consequences for folding, stability and availability 
of protein–protein interaction sites. Robust and repeatable func-
tional studies performed in clinical laboratories, however, have a 
significant role according to the ACMG guidelines.44
It was previously shown that the intact amino acid sequence 
of the TPR domains of AIP is essential for a proper interaction 
among amino acid residues in neighbouring alpha helices5; 
if these amino acids are changed by missense mutations, the 
resulted misfolded proteins are usually unstable.6 Various in vitro 
studies were employed to evaluate AIP variants, such as LOH 
analysis, splicing assays, cell proliferation, PDE4A5 binding 
and protein turnover.4 13 16 45 As we do not fully understand the 
mechanism of tumourigenesis induced by lack of AIP, the assay 
we might use in in vitro studies may not represent the true func-
tion of AIP. We demonstrated that AIP is an essential gene and 
several functional and comparative genomic analyses confirmed 
that essential genes are conserved during evolution.46–49 The fact 
that AIP is highly conserved among the species supports the fact 
that it is a disease-associated protein.50 As signalling pathways 
involved in organ development, cell proliferation, cell survival 
and cell migration are highly conserved in D. melanogaster,51 52 
the results of fruit fly studies were shown to be transferable to 
humans; more than half of the known human disease genes, 
have homologues in fruit fly.53 We employed a Drosophila model 
organism to discover the conserved role of AIP and to avoid 
potential confounding factors arising from the redundancy and 
variability that can be generated by the analysis of more complex 
organisms. However, in vivo experiments, such as our Drosophila 
bioassay, may not correctly predict the functionality of a variant. 
Mouse studies, although closer to humans than Drosophila, can 
also provide misleading conclusions in some diseases.54 However, 
the fact that we used the human AIP protein in our studies and 
that this was sufficient to rescue the developmental function of 
the Drosophila orthologue is potentially a major advantage of 
our in vivo system, and this could be an additional approach to 
help clinicians reach the right conclusion.
In summary, we have engineered an in vivo bioassay for charac-
terising patient-based AIP variants. The data presented support the 
evolutionary conservation of the AIP gene. Deletions of the endog-
enous Drosophila orthologue resulted in lethality of the flies, while 
the human gene can compensate for this loss. Rescue patterns of 
missense AIP variants can complement clinical and bioinformatics 
data and inform clinical decision making regarding AIP variants.8 16 
The benefit of cascade genetic screening and clinical follow-up has 
already been established in AIP mutation-positive families,3 55 56 
while family members in kindreds with non-pathogenic variants 
could be spared the psychological and financial burden of genetic 
testing and clinical follow-up.
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Table 1 Characterisation of AIP missense mutations identified in the various patients and investigated in this study
Variant MAF in GnomAD
Typical phenotype
(young, growth hormone (Gh)-secreting 
adenoma) lOh Functional data In silico prediction
Drosophila 
rescued
c.38T>A, p.I13N 8.25E-06 Young, GH-secreting adenoma Yes Not studied Probably damaging No
c.47G>A, p.R16H 0.001956 Familial cases, GH-secreting adenoma No Non-pathogenic Probably damaging Yes
c.217T>C, p.W73R 0 Young, GH-secreting adenoma Not studied Not studied Probably damaging No
c.491A>G, p.Q164R 0 Young, GH-secreting adenoma Not studied Not studied Benign Yes
c.713G>A, p.C238Y 8.42E-06 Familial cases, GH-secreting adenoma Yes Pathogenic Probably damaging No
c.815G>A, p.G272D 0 Elderly, GH-secreting adenoma Not studied Not studied Probably damaging No
c.878A>T, p.E293V 0 Elderly, GH-secreting adenoma Not studied Not studied Benign Yes
c.896C>T, p.A299V 4.00E-04 No Not studied Non-pathogenic Benign Yes
c.911G>A, p.R304Q 0.001458 Multiple cases No Non-pathogenic Benign Yes
c.940C>T, p.R314W 4.03E-05 Young, GH-secreting adenoma Not studied Not studied Probably damaging Yes
c.974G>A, p.R325Q 0.000058 Young, prolactin-secreting adenoma Yes Non-pathogenic Benign Yes
AIP, aryl hydrocarbon receptor-interacting protein gene; MAF, minor allele frequency.
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